The company's expertise in gene editing could lead to more breakthroughs.

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

Late last month, Anthropic claimed it had discovered a curious stretch of DNA in a virus called a bacteriophage that repeats ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Anthropic says 950 Claude agents scanned more than 200,000 reverse transcriptases in 21 hours, identifying a novel system called ART that researchers later validated in a laboratory ...

According to MarketsandMarkets™, the CRISPR Market is projected to reach USD 6.12 billion by 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period.

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear. But the work marks a major advancement because the A.I. made this discovery ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader ...

Delivering a compact CRISPR, "psCas12f," which can be turned on and off with light, via a single AAV, and performing genome editing "only where targeted" using focused ultrasound via light-emitting pa ...

Anthropic says its AI Claude has “autonomously discovered” a new enzyme system similar to machinery behind the powerful gene-editing tool Crispr. It’s the first result from Anthropic’s newly-launched ...